Serum/glucocorticoid-regulated kinase 1 expression in primary human prostate cancers

Prostate

Volumn 72, Issue 2, 2012, Pages 157-164

  Szmulewitz, Russell Z ^a   Chung, Elizabeth ^a   Al Ahmadie, Hikmat ^b   Daniel, Silver ^a   Kocherginsky, Masha ^a   Razmaria, Aria ^a   Zagaja, Gregory P ^a   Brendler, Charles B ^c   Stadler, Walter M ^a   Conzen, Suzanne D ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

androgen receptor; glucocorticoid receptor; prostate cancer; SGK1

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; GLUCOCORTICOID RECEPTOR; SERUM AND GLUCOCORTICOID REGULATED KINASE 1;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER GRADING; CANCER RECURRENCE; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; HUMANS; IMMEDIATE-EARLY PROTEINS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, ANDROGEN; RECEPTORS, GLUCOCORTICOID; TISSUE ARRAY ANALYSIS;

EID: 84455170555     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21416     Document Type: Article

References (40)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60 (5): 277-300.
2. Ward JF, Moul JW,. Rising prostate-specific antigen after primary prostate cancer therapy. Nat Clin Pract Urol 2005; 2 (4): 174-182. (Pubitemid 40823138)
3. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC,. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003; 169 (2): 517-523. (Pubitemid 36132976)
4. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC,. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281 (17): 1591-1597. (Pubitemid 29211767)
5. Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Walsh PC, Epstein JI, Partin AW,. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007; 69 (6): 1095-1101. (Pubitemid 46891611)
6. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ, Jr., Dotan ZA, Fearn PA, Kattan MW,. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006; 98 (10): 715-717. (Pubitemid 43821789)
7. Fradet Y,. Biomarkers in prostate cancer diagnosis and prognosis: Beyond prostate-specific antigen. Curr Opin Urol 2009; 19 (3): 243-246.
8. Fiorentino M, Capizzi E, Loda M,. Blood and tissue biomarkers in prostate cancer: State of the art. Urol Clin North Am 2010; 37 (1): 131-141, Table of Contents.
9. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ,. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 2002; 62 (4): 1008-1013. (Pubitemid 34160279)
10. Scher HI, Sawyers CL,. Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23 (32): 8253-8261. (Pubitemid 46211563)
11. Shanmugam I, Cheng G, Terranova PF, Thrasher JB, Thomas CP, Li B,. Serum/glucocorticoid-induced protein kinase-1 facilitates androgen receptor-dependent cell survival. Cell Death Differ 2007; 14 (12): 2085-2094. (Pubitemid 350131158)
12. Zou JX, Guo L, Revenko AS, Tepper CG, Gemo AT, Kung HJ, Chen HW,. Androgen-induced coactivator ANCCA mediates specific androgen receptor signaling in prostate cancer. Cancer Res 2009; 69 (8): 3339-3346.
13. Bolton EC, So AY, Chaivorapol C, Haqq CM, Li H, Yamamoto KR,. Cell- and gene-specific regulation of primary target genes by the androgen receptor. Genes Dev 2007; 21 (16): 2005-2017. (Pubitemid 47267287)
14. Tessier M, Woodgett JR,. Serum and glucocorticoid-regulated protein kinases: Variations on a theme. J Cell Biochem 2006; 98 (6): 1391-1407. (Pubitemid 44141846)
15. Sahoo S, Brickley DR, Kocherginsky M, Conzen SD,. Coordinate expression of the PI3-kinase downstream effectors serum and glucocorticoid-induced kinase (SGK-1) and Akt-1 in human breast cancer. Eur J Cancer 2005; 41 (17): 2754-2759. (Pubitemid 41607569)
16. Mikosz CA, Brickley DR, Sharkey MS, Moran TW, Conzen SD,. Glucocorticoid receptor-mediated protection from apoptosis is associated with induction of the serine/threonine survival kinase gene, sgk-1. J Biol Chem 2001; 276 (20): 16649-16654.
17. Wu W, Chaudhuri S, Brickley DR, Pang D, Karrison T, Conzen SD,. Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res 2004; 64 (5): 1757-1764. (Pubitemid 38428699)
18. Sherk AB, Frigo DE, Schnackenberg CG, Bray JD, Laping NJ, Trizna W, Hammond M, Patterson JR, Thompson SK, Kazmin D, Norris JD, McDonnell DP,. Development of a small-molecule serum- and glucocorticoid-regulated kinase-1 antagonist and its evaluation as a prostate cancer therapeutic. Cancer Res 2008; 68 (18): 7475-7483.
19. Rauhala HE, Porkka KP, Tolonen TT, Martikainen PM, Tammela TL, Visakorpi T,. Dual-specificity phosphatase 1 and serum/glucocorticoid-regulated kinase are downregulated in prostate cancer. Int J Cancer 2005; 117 (5): 738-745. (Pubitemid 41598824)
20. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA,. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351 (15): 1502-1512. (Pubitemid 39315317)
21. Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN, Jr., Jones JA, Taplin ME, Burch PA, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED,. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 2006; 98 (8): 516-521. (Pubitemid 43898814)
22. Fakih M, Johnson CS, Trump DL,. Glucocorticoids and treatment of prostate cancer: A preclinical and clinical review. Urology 2002; 60 (4): 553-561. (Pubitemid 35246431)
23. Yemelyanov A, Czwornog J, Chebotaev D, Karseladze A, Kulevitch E, Yang X, Budunova I,. Tumor suppressor activity of glucocorticoid receptor in the prostate. Oncogene 2007; 26 (13): 1885-1896. (Pubitemid 46474637)
24. Mohler JL, Chen Y, Hamil K, Hall SH, Cidlowski JA, Wilson EM, French FS, Sar M,. Androgen and glucocorticoid receptors in the stroma and epithelium of prostatic hyperplasia and carcinoma. Clin Cancer Res 1996; 2 (5): 889-895. (Pubitemid 26168942)
25. Lotan TL, Lyon M, Huo D, Taxy JB, Brendler C, Foster BA, Stadler W, Rinker-Schaeffer CW,. Up-regulation of MKK4, MKK6 and MKK7 during prostate cancer progression: An important role for SAPK signalling in prostatic neoplasia. J Pathol 2007; 212 (4): 386-394. (Pubitemid 47099015)
26. Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM, Bhargava R,. Androgen receptor in breast cancer: Expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol 2010; 23 (2): 205-212.
27. Belova L, Delgado B, Kocherginsky M, Melhem A, Olopade OI, Conzen SD,. Glucocorticoid receptor expression in breast cancer associates with older patient age. Breast Cancer Res Treat 2009; 116 (3): 441-447.
28. Chan TY, Partin AW, Walsh PC, Epstein JI,. Prognostic significance of Gleason score 3 + 4 versus Gleason score 4 + 3 tumor at radical prostatectomy. Urology 2000; 56 (5): 823-827.
29. Wright JL, Salinas CA, Lin DW, Kolb S, Koopmeiners J, Feng Z, Stanford JL,. Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort. J Urol 2009; 182 (6): 2702-2707.
30. Klein JP, Logan B, Harhoff M, Andersen PK,. Analyzing survival curves at a fixed point in time. Stat Med 2007; 26 (24): 4505-4519. (Pubitemid 47534694)
31. Sterbis JR, Gao C, Furusato B, Chen Y, Shaheduzzaman S, Ravindranath L, Osborn DJ, Rosner IL, Dobi A, McLeod DG, Sesterhenn IA, Srivastava S, Cullen J, Petrovics G,. Higher expression of the androgen-regulated gene PSA/HK3 mRNA in prostate cancer tissues predicts biochemical recurrence-free survival. Clin Cancer Res 2008; 14 (3): 758-763. (Pubitemid 351231157)
32. Donovan MJ, Osman I, Khan FM, Vengrenyuk Y, Capodieci P, Koscuiszka M, Anand A, Cordon-Cardo C, Costa J, Scher HI,. Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease. BJU Int 105 (4): 462-467.
33. Rosner IL, Ravindranath L, Furusato B, Chen Y, Gao C, Cullen J, Sesterhenn IA, McLeod DG, Srivastava S, Petrovics G,. Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy. Urology 2007; 70 (6): 1225-1229. (Pubitemid 350297391)
34. Li R, Wheeler T, Dai H, Frolov A, Thompson T, Ayala G,. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: Cancer patients treated with radical prostatectomy. Am J Surg Pathol 2004; 28 (7): 928-934. (Pubitemid 38856850)
35. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Kong X, Melamed J, Tepper CG, Kung HJ, Brodie AM, Edwards J, Qiu Y,. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 2009; 69 (6): 2305-2313.
36. Koochekpour S,. Androgen receptor signaling and mutations in prostate cancer. Asian J Androl 2010; 12 (5): 639-657.
37. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H, Nelson PS, Plymate SR,. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 2010; 120 (8): 2715-2730.
38. Cleutjens CB, Steketee K, van Eekelen CC, van der Korput JA, Brinkmann AO, Trapman J,. Both androgen receptor and glucocorticoid receptor are able to induce prostate-specific antigen expression, but differ in their growth-stimulating properties of LNCaP cells. Endocrinology 1997; 138 (12): 5293-5300. (Pubitemid 27509690)
39. Ho KC, Marschke KB, Tan J, Power SG, Wilson EM, French FS,. A complex response element in intron 1 of the androgen-regulated 20-kDa protein gene displays cell type-dependent androgen receptor specificity. J Biol Chem 1993; 268 (36): 27226-27235. (Pubitemid 24006442)
40. Chen S, Wang J, Yu G, Liu W, Pearce D,. Androgen and glucocorticoid receptor heterodimer formation. A possible mechanism for mutual inhibition of transcriptional activity. J Biol Chem 1997; 272 (22): 14087-14092. (Pubitemid 27232812)